When we use words to communicate, we not only have to choose what to say, but also what not to say, and how to say it. How we decide to frame a message can influence how people think, feel, and ...

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Recursion Pharmaceuticals, Inc. before investing. In this article, we go over a ...

Dashia is the consumer insights editor for CNET. She specializes in data-driven analysis and news at the intersection of tech, personal finance and consumer sentiment. Dashia investigates economic ...

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...

The de-risking event relates to the acquisition of the 50% interest in an ENPP1 inhibitor program (REV102) that it didn't own from Rallybio (NASDAQ: RLYB). REV102 is being developed to treat ...

Recursion Pharmaceuticals is now the sole owner of a drug in its pipeline. The deal de-risks the company's pipeline by removing uncertainty; however, there's still a long way to go before REV102 is ...

With burgers sizzling and classic rock thumping, many Americans revel in summer cookouts – at least until that wayward cousin asks for a “pop” in soda country, or even worse, a “coke” when they ...

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.27, marking a +1.15% move from the previous day. The stock's performance was ahead of the S&P 500's daily gain of 0.83%. At ...

"It's not the heat. It's the humidity." Sound familiar? I think we're all guilty of saying that at some point between June and September. The heat index isn't just some made-up number to inflate ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...